

AD \_\_\_\_\_

GRANT NUMBER: DAMD17-94-J-4287

TITLE: Analysis of the Regulation of Expression of  
Transforming Growth Factor-Beta in Human Breast Cancer  
Cells

PRINCIPAL INVESTIGATOR: Bradley A. Arrick, M.D., Ph.D.

CONTRACTING ORGANIZATION: Dartmouth College  
Hanover, New Hampshire 03755-3580

REPORT DATE: October 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19960510 080

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE October 1995	3. REPORT TYPE AND DATES COVERED Annual 1 Oct 94 - 30 Sep 95		
4. TITLE AND SUBTITLE Analysis of the Regulation of Expression of Transforming Growth Factor-Beta in Human Breast Cancer Cells		5. FUNDING NUMBERS DAMD17-94-J-4287		
6. AUTHOR(S) Bradley A. Arrick, M.D., Ph.D.,				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Dartmouth College Hanover, New Hampshire 03755-3580		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited		12b. DISTRIBUTION CODE		
13. ABSTRACT (Maximum 200 words) This grant entails two objectives. These objectives derived from prior work by ourselves and others which have identified TGF- $\beta$ as an important cytokine in the biology of breast cancer. For established tumors, overexpression of TGF- $\beta$ may result in increased in vivo tumor growth and metastatic spread. The first objective involves the analysis of resected breast cancer specimens, with the ultimate goal of determining the mechanism(s) by which TGF- $\beta$ could be overexpressed by some tumors. There are as yet no definitive data or conclusions from this aspect of the work. The second objective of the grant was to identify the molecular determinants of promoter usage for TGF- $\beta$ 3 in breast cancer cells. These studies stem from our prior work in which we have characterized an alternative TGF- $\beta$ 3 promoter uniquely functional in breast cancer cells. We have made some progress in designing promoter constructs which yield authentic promoter function upon transfection into breast cancer cells. The Statement of Work did not call for any conclusions by this point in the grant, and none are available.				
14. SUBJECT TERMS gene expression, promoter analysis, TGF- $\beta$ , breast cancer		15. NUMBER OF PAGES 7		
		16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to **stay within the lines** to meet **optical scanning requirements**.

**Block 1. Agency Use Only (Leave blank).**

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

<b>C</b> - Contract	<b>PR</b> - Project
<b>G</b> - Grant	<b>TA</b> - Task
<b>PE</b> - Program Element	<b>WU</b> - Work Unit Accession No.

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

**Block 12b. Distribution Code.**

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

*RAI* For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

*RAI* In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

*RAI* In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories. ....

  
PI - Signature

18/20/95  
Date

## **REVISED ANNUAL REPORT**

**Grant Number DAMD17-J-4287**

**PI:** Bradley A. Arrick, M.D., Ph.D.

**Institution:** Dartmouth College

**Reporting Period:** 10/1/94-9/30/95

**Title:** Analysis of the Regulation of Expression of Transforming Growth Factor-Beta in Human Breast Cancer Cells.

### **Introduction**

This grant entails two objectives. These objectives derived from prior work by ourselves and others which have identified TGF- $\beta$  as an important cytokine in the biology of breast cancer. For established tumors, overexpression of TGF- $\beta$  may result in increased in vivo tumor growth and metastatic spread (Gorsch et al. 1992). The first objective involves the analysis of resected breast cancer specimens, with the ultimate goal of determining the mechanism(s) by which TGF- $\beta$  could be overexpressed by some tumors. The second objective of the grant was to identify the molecular determinants of promoter usage for TGF- $\beta$ 3 in breast cancer cells. These studies stem from our prior work in which we have characterized an alternative TGF- $\beta$ 3 promoter uniquely functional in breast cancer cells (Arrick et al. 1994).

### **Body of First Yearly Report**

#### **First Objective (Objective A)**

We had previously reported that intensity of anti-TGF- $\beta$ 1 immunoreactivity within breast cancer specimens correlated with poor clinical outcome (Gorsch et al., 1992). That study involved 57 heterogeneous patients. As an initial effort, we felt it important to confirm that observation by analysis of a larger number of tumor specimens from a homogeneous set of patients. We have recently completed the analysis of anti-TGF- $\beta$ 1 immunoreactivity in approximately 140 patients who had node-positive breast cancer and were treated as part of a multi-institutional clinical trial (by the CALGB cooperative group). Statistical analysis of these data, with correlation with markers of angiogenesis performed by collaborators, will begin shortly. Overall, among this group roughly 20% of patients were found to have tumors which overexpressed TGF- $\beta$ 1, 20% were determined to be underexpressors of TGF- $\beta$ 1, and the remainder (approximately 60%) were graded as expressing normal amounts of TGF- $\beta$ 1 protein.

Awaiting the analysis of the immunohistochemical data, we have conducted preliminary experiments to determine the optimal method of processing frozen tissue so as to obtain protein, DNA, and RNA of sufficient quality for subsequent quantitative analysis. We have compared grinding frozen tissue into a powder under liquid nitrogen using mortar and pestle with the use of a "tissue pulverizer" which essentially

allows one to whack at it with a hammer. The optimal method for tissue handling turned out to be a combination of the two, although we have yet to compare with a motor-driven homogenizer. We have had difficulty in obtaining RNA of high quality, that is to say without evident degradation, and so are exploring alternative freezing and processing procedures.

The *Statement of Work* in the grant application did not call for the completion of studies within this objective within the first year -- we aim to determine whether those tumors which overexpress TGF- $\beta$ 1 protein do so as a result of gene amplification of the TGF- $\beta$ 1 gene locus by the conclusion of the 18th month of the grant. Since the determination of the frequency of gene amplification is essentially a function of comparative PCR, this analysis of the genomic DNA from the frozen specimens must await the collection of a sufficient number of quality specimens. It would be inappropriate to compare PCR results from reactions conducted over a span of many months. We anticipate being able to report these results in the second yearly report.

### Second Objective

The entirety of this objective is to understand the molecular basis by which breast cancer cells, unlike all other cell types examined by ourselves and others, utilize a different promoter for transcription of the TGF- $\beta$ 3 gene (Arrick et al., 1994). Our initial intention was to devote the first 18 months of the grant to the analysis of DNaseI hypersensitivity and genomic methylation in the vicinity of the TGF- $\beta$ 3 promoter. We had planned to not pursue experiments involving transfection of TGF- $\beta$ 3 promoter constructs until after the first 1.5 years of the grant. As we will describe below, we have since decided to work on both of these fronts during the first year.

### Experiments for Objectives B-1 and B-2

DNase hypersensitivity assays were conducted as outlined in the grant proposal. In summary, cells (both breast cancer cell lines which express both transcripts of TGF- $\beta$ 3 and non breast cancer cell lines which express only the 3.5 kb transcript of TGF- $\beta$ 3) were grown to near confluence in 6 cm dishes in standard serum-containing medium. They were, while still adherent in the culture dishes, treated with DNase I at doses of 0, 2, 20, and 200 units/ml in the permeabilizing solution of Stewart et al (Nucleic Acid Research 19: 3157) for 4 min at RT, at which time the genomic DNA was isolated. This was then digested with BglII overnight and applied to a 1% agarose gel. Ethidium bromide staining revealed the expected "smear" of genomic DNA. This was transferred by capillary transfer to nylon membrane and probed with radiolabeled probe which was the BsU36I-BglII fragment from the TGF- $\beta$ 3 genomic clone. No differences in hybridizing band patterns was evident between cells which utilize the downstream TGF- $\beta$ 3 promoter (we tested T47-D and SK-BR-3) compared with cells which only utilized the upstream TGF- $\beta$ 3 promoter (HT-1080 and A-673 cells were tested). We also isolated nuclei from these cells by hypotonic lysis and treated the intact nuclei with the



same range of DNase I concentrations, prepared genomic DNA and analyzed the DNA exactly as outlined above. Again, we did not detect any differences among the cells.

Using the genomic DNA preparations from the cells not treated with DNase I we also analyzed for differences in methylation at HpaII vs MspI restriction sites by digesting overnight with either of these two enzymes, and including these digests in southern analysis as outlined above. This is a limited analysis of methylation status, but there were no differences between cells noted. The more robust methods outlined in the proposal involving sequencing require some prior knowledge of the approximate area of genomic DNA involved in the regulation of expression. It has thus become evident that efficient analysis of genome structure (methylation, DNase hypersensitivity) would be optimal if we could narrow our focus by comparison of a panel of expression constructs containing varying amounts of 5' flanking sequence.

### Experiments for Objective B-3

Although the Statement of Work did not call for any experimental efforts towards the completion of this objective, as discussed above, we have since decided that information that might be obtained by these experiments could facilitate the successful completion of objectives B-1 and B-2, and so have begun work on objective B-3.

The preliminary data regarding promoter activity that were presented in the grant application were obtained with a chimeric promoter-CAT construct which contained an enhancer element from the SV40 virus. In addition, that plasmid did not contain any sequences upstream of commonly-utilized TGF- $\beta$ 3 promoter (P1). We first prepared by standard subcloning techniques the two additional constructs outlined in Fig 9 of the proposal, ones which contain sequences which will also activate P1. To avoid confounding effects of the SV40 enhancer, this was removed. Transient transfection of these constructs into cells (HT-1080, SK-BR-3, T47-D, and A673) did not result in high levels of CAT activity, and RNA analysis of the transfected cells failed to reveal detectable levels of CAT-specific RNA. These experiments were conducted many times, using a range of transfection techniques (Ca-phosphate precipitation, lipofectin, lipofectamine), and RNA analysis was done by standard Northern blotting as well as RNase protection assays.

To try to optimize expression, we prepared the following construct: the putative TGF- $\beta$ 3 promoter sequence was placed upstream of the neomycin resistance gene in an otherwise-promoterless plasmid. We have transfected with this construct T47-D and SK-BR-3 cells and have selected for stable transfectants by incubation of the cells in the presence of G418. We have recently done our first Northern with RNA from a few such clones, probing for RNA containing the neo resistance gene cDNA sequence, and believe that this will serve as a somewhat cumbersome but effective approach to this problem.

### **References Cited**

- Arrick, Bradley A., Richard L. Grendell, and Loree A. Griffin. 1994. Enhanced translational efficiency of a novel transforming growth factor- $\beta$ 3 mRNA in human breast cancer cells. *Molecular and Cellular Biology* 14:619-628.
- Gorsch, Stefan M. Vincent A. Memoli, Thérèse A. Stukel, Leslie I. Gold, and Bradley A. Arrick. 1992. Immunohistochemical staining for transforming growth factor- $\beta$ 1 associates with disease progression in human breast cancer. *Cancer Research* 52: 6949-6952.